SAN DIEGO, March 21, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation technologies, has announced its patented recombinant immunoglobulin peptide (IgP) technology creates a highly specific and superior antibody therapeutic. MultiCell's patented IgP antibody therapeutics are a new class of human antibody therapeutics engineered using recombinant DNA technology to contain disease-associated, T-cell responsive, therapeutic peptides.
